U.S. drugmaker Regeneron Pharmaceuticals on Thursday reported weaker-than-expected quarterly sales of the higher dose version ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

Regeneron Pharmaceuticals (REGN) stock falls despite Q3 beat, a move attributed to lower-than-expected sales for its high-dose Eylea therapy. Read more here.

With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company, ...

Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.

The nearer-looming threat of a biosimilar from Amgen Inc. to heavyweight Regeneron Pharmaceuticals Inc.’s age-related macular ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) stock is trading higher on Monday after the company revealed interim 16-week data ...

This NMA serves to bridge the gap between trials for both therapies and compare them to one another based on existing data.

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as ...

Canaccord Genuity analyst John Newman has maintained their bullish stance on REGN stock, giving a Buy rating today. John Newman has given his ...